# deLIVER: Direct Acting Antiviral Effects on the Liver

> **NCT02938013** · PHASE4 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 15 (actual)

## Conditions studied

- HCV Coinfection
- Liver Disease
- HIV

## Interventions

- **DRUG:** Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
- **DRUG:** Sofosbuvir/Velpatasvir (SOF/VEL)

## Key facts

- **NCT ID:** NCT02938013
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2019-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938013, "deLIVER: Direct Acting Antiviral Effects on the Liver". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02938013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*